At the 7th China International Import Expo (CIIE), Japan-based Eisai Co., Ltd (TYO: 4523) entered into a Memorandum of Understanding (MoU) with US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC). The partnership, centered on the early detection, precise diagnosis, and treatment of Alzheimer’s disease (AD), aims to enhance the early detection of AD and improve patient prognosis and quality of life by promoting clinical research and streamlining clinical diagnosis and treatment pathways.
Eisai’s Alzheimer’s Disease Drug and Integrated Solution with GE Healthcare
Eisai, known for co-developing Leqembi (lecanemab) with Biogen Inc. (NASDAQ: BIIB), showcased an integrated ecological solution for the precise diagnosis and treatment of AD at the event for the first time. Leqembi is the first AD therapy to receive full approval in the US in two decades, marking a significant advancement in the field.- Flcube.com
